Capricor Therapeutics Inc

CAPR remains entrenched in a Stage 4 decline with clear lower highs and lower lows beneath declining EMAs. Price is extended and oversold, signaling exhaustion, but without any decisive upside displacement to invalidate bearish control. The medium-term bias stays bearish, so we defer execution until relief rallies into the EMA and prior resistance zone, where we sell into strength.

• ↑HOPE III trial: Daromyosal slowed LV ejection decline by 91%
• ↑FDA review on track with PDUFA set for Aug 22, 2026; no major issues raised
• ↓Q1 2026 net loss $33.9M ($0.59/share) vs $24.4M a year earlier